YL Biologics (YLB), the Japan-based joint venture of Lupin and local firm Yoshindo, says its YLB113 biosimilar etanercept candidate met its primary endpoint in a global Phase III clinical trial comparing the efficacy and safety of the biosimilar in patients with rheumatoid arthritis against Amgen’s Enbrel (etanercept) original.
YL Biologics (YLB), the Japan-based joint venture of Lupin and local firm Yoshindo, says its YLB113 biosimilar etanercept candidate met its primary endpoint in a global Phase III clinical trial comparing the efficacy and safety of the biosimilar in patients with rheumatoid arthritis against Amgen’s Enbrel (etanercept) original.
The biosimilar was found to be within a “pre-defined equivalence margin” of the American College of Rheumatology 20 (ACR20) response...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
